Through our partner, AMSBIO, we offer high quality, next generation in vitro disease models that reflect the unique nature of a patient’s biology. All our models begin with a patient specimen, traceable to clinically relevant details that inform model characterization. By broadening patient representation, our models enable researchers and innovators to gain insights for the development of the next generation of personalized therapeutics.

Using proprietary technology and methods, we preserve the patient-specific and disease-oriented cells in stable, long-term cell models. We combine specialized expertise with our integrated outreach services to source, profile and model desired cell types. For cancer, these cell models exhibit molecular and phenotypic characteristics that are highly concordant with the patient. For RNA-mediated iPS cell line derivation, cell models enable integration of disease-specific mechanisms of action.